Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 11/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7921087 | 0.79 | AHR (0.46) | AHRGAAAPPNPC1RAB9A | |
| SCHEMBL12825740 | 0.79 | AHR (0.61) | AHRPIK3CGGAAAPPNPC1 | |
| SCHEMBL22438963 | 0.76 | DYRK1A (0.38) | AHRPIK3CGAPPNPC1RAB9A | |
| SCHEMBL5930721 | 0.76 | DYRK1A (0.38) | AHRPIK3CGAPPDYRK1ATGFBR1 | |
| SCHEMBL10271997 | 0.76 | AHR (0.51) | AHRGAAAPPNPC1RAB9A | |
| SCHEMBL12779142 | 0.76 | DYRK1A (0.38) | AHRPIK3CGDYRK1ATGFBR1 | |
| SCHEMBL43051 | 0.76 | AHR (0.58) | AHRPIK3CGAPPTSHRMAPK10 | |
| SCHEMBL27038621 | 0.76 | AHR (0.60) | AHRPIK3CGGAAAPPNPC1 | |
| SCHEMBL21929912 | 0.76 | AHR (0.53) | AHRPIK3CGGAAAPPNPC1 | |
| SCHEMBL16439342 | 0.76 | AHR (0.53) | AHRPIK3CGGAAAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4661964-A1 | COMPOUNDS AS CCR6 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-12-17 | — | — | EP | disclosed |
| US-20250353859-A1 | COMPOUNDS AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4630402-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| WO-2025111547-A1 | 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF | RGENTA THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| WO-2024165453-A1 | COMPOUNDS AS CCR6 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-08-15 | — | — | WO | disclosed |
| WO-2024121013-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-06-13 | — | — | WO | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| EP-2393813-B1 | Cyclic inhibitors of 11 ß-hydroxysteroid dehydrogenase 1 useful for the treatment of diseases related to elevated level of cortisol | VITAE PHARMACEUTICALS INC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20120040973-A1 | DERIVATIVES OF [1,3]OXAZIN-2-ONE USEFUL FOR THE TREATMENT OF METABOLIC DISEASES SUCH AS LIPID DISORDERS | VITAE PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040973-A1 | DERIVATIVES OF [1,3]OXAZIN-2-ONE USEFUL FOR THE TREATMENT OF METABOLIC DISEASES SUCH AS LIPID DISORDERS | VITAE PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040973-A1 | DERIVATIVES OF [1,3]OXAZIN-2-ONE USEFUL FOR THE TREATMENT OF METABOLIC DISEASES SUCH AS LIPID DISORDERS | VITAE PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2393813-A2 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20110098471-A1 | OXAZOLIDINONE DERIVATIVE HAVING FUSED RING | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110098471-A1 | OXAZOLIDINONE DERIVATIVE HAVING FUSED RING | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110098471-A1 | OXAZOLIDINONE DERIVATIVE HAVING FUSED RING | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2011-04-28 | — | — | US | disclosed |
| WO-2010091067-A2 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010091067-A2 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | AHR 164/4885PIK3CG 2566/4885GAA 2023/4885 |
| US-20110098471-A1 | OXAZOLIDINONE DERIVATIVE HAVING FUSED RING | OXER1, ALOX12, CYP1A1 | AHR 20/4885PIK3CG 4537/4885GAA 4530/4885 |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | AHR 271/4885PIK3CG 3979/4885GAA 3694/4885 |
| US-20120040973-A1 | DERIVATIVES OF [1,3]OXAZIN-2-ONE USEFUL FOR THE TREATMENT OF METABOLIC DISEASES SUCH AS LIPID DISORDERS | HSD11B1, HSD11B2, HSD17B1 | AHR 3002/4885PIK3CG 1914/4885GAA 726/4885 |
| US-20250353859-A1 | COMPOUNDS AS CCR6 INHIBITORS | CCR6, CCR4, CCR1 | AHR 576/4885PIK3CG 3285/4885GAA 3474/4885 |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | AHR 148/4885PIK3CG 2427/4885GAA 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.